首页> 外文期刊>Neuropsychopharmacology >Association of 4-Repeat Allele of the Dopamine D4 Receptor Gene Exon III Polymorphism and Response to Methylphenidate Treatment in Korean ADHD Children
【24h】

Association of 4-Repeat Allele of the Dopamine D4 Receptor Gene Exon III Polymorphism and Response to Methylphenidate Treatment in Korean ADHD Children

机译:多动症D4受体基因外显子III多态性的4重复等位基因与韩国ADHD儿童对哌醋甲酯反应的相关性。

获取原文
       

摘要

In the present study, we investigated the association between the 4-repeat allele at the dopamine receptor D4 (DRD4) gene and the response to treatment with methylphenidate (MPH) in Korean children with attention deficit hyperactivity disorder (ADHD). The study subjects were 83 children with ADHD (8.401.73 years) who were recruited from two child psychiatric clinics in South Korea. All of the drug-naive ADHD children were treated with MPH for about 8 weeks. An improvement of more than 50% in the ADHD Rating Scale-IV (ARS) scores after 8 weeks of treatment compared with the baseline ARS scores before the treatment was considered as a 'good response', whereas an improvement of less than (or equal to?) 50% was considered as a 'poor response'. After the genotyping for DRD4 was performed, we investigated the association between the genotype at DRD4 and the response to MPH treatment. We performed a comparison of the response to MPH treatment between the two largest groups, viz. the subjects with and without the 4/4 genotype at DRD4. According to the ARS scores of the subjects as assessed by their parents and by their teachers, we found that while 71.1 and 80.0% (32/45 and 24/30), respectively, of those with a good response to MPH treatment showed the 4/4 genotype at DRD4, only 31.6 and 37.7% (12/38 and 20/53), respectively, of those with a poor response to MPH treatment showed the 4/4 genotype at DRD4 (Pearson 2-values=12.926 and 13.737, respectively, both df=1, and both p<0.01). Our findings support the existence of an association between the 4-repeat allele at DRD4 and good response to MPH in Korean ADHD children.
机译:在本研究中,我们调查了韩国注意力缺陷多动障碍(ADHD)儿童多巴胺受体D4(DRD4)基因的4重复等位基因与哌醋甲酯(MPH)治疗反应之间的关联。研究对象是从韩国两家儿童精神病诊所招募的83名ADHD儿童(8.401.73岁)。所有未吸毒的多动症儿童均接受MPH治疗约8周。与治疗前的基线ARS得分相比,治疗8周后的ADHD评分-IV(ARS)得分提高了50%以上,被认为是“良好的反应”,而低于(或等于?)50%被认为是“反应不佳”。对DRD4进行基因分型后,我们调查了DRD4的基因型与MPH治疗反应之间的关联。我们比较了两个最大的群体对MPH治疗的反应。在DRD4有和没有4/4基因型的受试者。根据他们的父母和老师评估的受试者的ARS分数,我们发现,对MPH治疗反应良好的受试者分别有71.1%和80.0%(32/45和24/30)显示出在DRD4处的4/4基因型分别只有31.6和37.7%(12/38和20/53),对MPH治疗反应较差的人在DRD4处显示4/4基因型(Pearson 2值= 12.926和分别为13.737,df = 1和p <0.01)。我们的研究结果支持DRD4处的4重复等位基因与韩国ADHD儿童对MPH的良好反应之间存在关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号